Business

Pfizer's Biosimilar Revenues Soar 80%

October 27th 2020

By Tony Hagen

The strong growth of biosimilars Pfizer recently launched in the United States are part of the success story, although reference etanercept (Enbrel) sales have seen major erosion.

Alvotech Locks In $65 Million for Biosimilar Development

October 27th 2020

By Tony Hagen

With a sizeable round of fresh capital, Alvotech hopes to bring monoclonal antibodies and fusion proteins through the development pipeline.

Biogen, Samsung Report Third-Quarter Biosimilar Results

October 21st 2020

By Tony Hagen

Earnings fell overall for Biogen, although biosimilar revenues continued an upward climb.

Avalere: Step Therapy May Exacerbate Patient, Payer Costs

October 19th 2020

By Tony Hagen

An Avalere analysis suggests costs are more moderate and lower under a no–step therapy scenario for patients with Crohn disease.

Roche Earnings Hit by Biosimilar Competition, COVID-19

October 16th 2020

By Tony Hagen

Roche attributes a $3.83 billion reduction in sales to biosimilar competition.

Revance Reports Positive Findings for Potential Botox Competitor

October 15th 2020

By Tony Hagen

DaxibotulinumtoxinA met all end points in a study demonstrating longer duration of action, safety, and tolerability.

Study: Efficacy Trials Cost More, Take Longer for Biosimilars Than Originators

October 10th 2020

By Skylar Jeremias

Average clinical efficacy testing cost millions of dollars more for phase 3 biosimilar studies than for pivotal studies of originator products, authors report.

Part 2: Ryan Cox on Whether Midsize Employers Have a Voice in Biosimilar Discussions

October 8th 2020

Ryan Cox, vice president of the Access Experience Team at PRECISIONvalue, discusses whether midsize employers can participate in payer discussions on formulary placement.

Part 1: Ryan Cox on What Employers Need to Do to Boost Biosimilar Uptake

October 7th 2020

Ryan Cox, vice president of the Access Experience Team at PRECISIONvalue, discusses what employers can do to encourage biosimilar uptake and what cultural changes are needed to make it happen.

IQVIA: Biosimilars Could Save $100 Billion Over Next 5 Years

October 6th 2020

By Skylar Jeremias

A report from the IQVIA Institute for Human Data Science states that assessments of the health of the US biosimilar market are too conservative.